Antioxidant peptides from Antarctic krill (Euphausia superba) hydrolysate: Stability, ACE inhibitory activity, and endothelial cells protection by regulating Keap1/Nrf2 pathway

The objective of this work was to study the angiotensin-I-converting enzyme (ACE) inhibitory (ACEi) activity, inhibition mechanism, and ameliorating functions of SLPY, QYPPMQY and EYEA on HUVECs damaged by oxidative stress. The results indicated that SLPY, QYPPMQY and EYEA could significantly inhibit ACE activity with IC 50 values of 0.3715, 0.2903 and 0.3375 mg/mL, respectively; the affinity of SLPY, QYPPMQY and EYEA with ACE was −8.1, −9.9, and −8.3 kcal/mol, respectively, which is mainly due to the hydrophobic interaction and hydrogen bonding between peptide and ACE. Moreover, SLPY, QYPPMQY and EYEA could significantly improve the viability of H 2 O 2 -damaged HUVECs. The mechanism showed that SLPY, QYPPMQY and EYEA could activate the Keap1/Nrf2 pathway in HUVECs through significantly up-regulating Nrf2 protein expression and level in the nucleus ( P < 0.05), which subsequently improved the activity of downstream proteases, increased the NO production, and reduced the levels of ROS, MDA and LDH. Moreover, molecular docking results illustrated that SLPY, QYPPMQY and EYEA could regulate Keap1/Nrf2 pathway by non-competitive inhibition model. Then, SLPY, QYPPMQY and EYEA could ameliorate hypertension via significantly inhibiting ACE activity and effectively protecting HUVECs against oxidative damage, and these results provide theoretical support for developing health products for curing hypertension and its closely related cardiovascular diseases. • SLPY, QYPPMQY and EYEA are separated from Antarctic krill hydrolysate. • SLPY, QYPPMQY and EYEA can significantly inhibit ACE activity. • SLPY, QYPPMQY and EYEA can significantly protect HUVECs against oxidative damage. • SLPY, QYPPMQY and EYEA reduce the oxidative damage via activating Keap1/Nrf2 pathway. • SLPY, QYPPMQY and EYEA are suitable for health products to ameliorate hypertension.